Progression-free survival (A) and DLBCL-specific survival (B) of all patients. Strong Trx intensity was associated with both poor progression-free (C) and disease-specific (D) survival. Nitrotyrosine as a marker of nitrosative stress was a marker of poor prognosis (E). GCL-positive patients had worse disease-specific survival (F) and a trend towards shorter disease-specific survival (G). Patients with strong nitrotyrosine and/or Trx expression had significantly worse relapse-free (H) and DLBCL-specific (I) survival than other patients. Trx intensity was a powerful prognostic indicator in the non-GC group (J), but not in patients with GC phenotype.